-
Je něco špatně v tomto záznamu ?
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial
A. Egle, T. Melchardt, P. Obrtlíková, L. Smolej, T. Kozák, M. Steurer, J. Andel, S. Burgstaller, E. Mikušková, L. Gercheva, T. Nösslinger, T. Papajík, M. Ladická, M. Girschikofsky, M. Hrubiško, U. Jäger, D. Voskova, M. Pecherstorfer, E....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie
NLK
Directory of Open Access Journals
od 2012
Free Medical Journals
od 2012
PubMed Central
od 2012
Europe PubMed Central
od 2012
ProQuest Central
od 2012-08-01
Open Access Digital Library
od 2012-01-01
Open Access Digital Library
od 2012-01-01
Health & Medicine (ProQuest)
od 2012-08-01
Wiley Free Content
od 2012
Wiley-Blackwell Open Access Titles
od 2012
ROAD: Directory of Open Access Scholarly Resources
od 2012
PubMed
30888118
DOI
10.1002/cam4.1980
Knihovny.cz E-zdroje
- MeSH
- analýza přežití MeSH
- chronická lymfatická leukemie farmakoterapie mortalita MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- obezita komplikace mortalita MeSH
- prognóza MeSH
- rituximab aplikace a dávkování terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- udržovací chemoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL-8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab-containing induction treatment in first or second line that had achieved at least a PR. A randomization to rituximab maintenance treatment (375 mg/m2 q3 months for 2 years) vs observation was performed. In this cohort 22% of the patients (58/263) were classified as obese. The baseline response to induction treatment was inferior in obese patients with a lower CR rate (43.1% vs 60.5% in obese vs non-obese, P = 0.018) and with a lower rate of patients achieving MRD negativity after chemoimmunotherapy induction treatment (19.6% vs 35.8%, P = 0.02). The PFS outcome of obese patients was significantly worse in the observation group of the trial (24 vs 39 months median PFS, P = 0.03). However, in the rituximab maintenance group the outcome for obese vs non-obese was not different (P = 0.4). In summary, obesity was overall associated with a worse outcome of chemoimmunotherapy induction. However, rituximab maintenance treatment seems to be able to overcome this negative effect.
Assign Data Management and Biostatistics GmbH Innsbruck Austria
Clinic of Haematology Regional Institute of Oncology Iasi Iasi Romania
Clinic of Hematology UMHAT St George and Medical University Plovdiv Plovdiv Bulgaria
Clinic of Hematology University Hospital St Marina Varna Varna Bulgaria
Clinic of Medical Hematology Military Medical Academy Sofia Sofia Bulgaria
Department of Clinical Hematology FNsP J A Reimana Prešov Prešov Slovakia
Department of Clinical Oncology 1 National Cancer Institute Bratislava Bratislava Slovakia
Department of Hemato oncology 2 National Cancer Institute Bratislava Bratislava Slovakia
Department of Hemato oncology University Hospital Olomouc Olomouc Czech Republic
Department of Hematology and Transfusion University Hospital Martin Martin Slovakia
Department of Hematology FNsP F D Roosevelta Banská Bystrica Banska Bystrica Slovakia
Department of Internal Medicine 3 Kepler Universitätsklinikum GmbH Med Campus 3 Linz Austria
Department of Internal Medicine 4 Klinikum Wels Grieskirchen GmbH Wels Austria
Department of Internal Medicine 5 Medical University Innsbruck Innsbruck Austria
Faculty of Medicine and CEITEC University Hospital Brno Brno Czech Republic
Hematological Clinic NSHATHD Sofia Queen Joanna University Hospital Sofia Bulgaria
Innere Medizin 1 Ordensklinikum Linz GmbH Linz Austria
Innere Medizin 2 Bezirkskrankenhaus Kufstein Kufstein Austria
Innere Medizin Landeskrankenhaus Hall Hall in Tirol Austria
Internal Medicine 2 Hospital of Steyr Steyr Austria
Interne Abteilung Ordensklinikum Linz GmbH Elisabethinen Linz Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20022794
- 003
- CZ-PrNML
- 005
- 20201214124820.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/cam4.1980 $2 doi
- 035 __
- $a (PubMed)30888118
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Egle, Alexander $u Third Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria. Salzburg Cancer Research Institute (SCRI), Salzburg, Austria. Cancer Cluster Salzburg (CCS), Salzburg, Austria.
- 245 10
- $a Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial / $c A. Egle, T. Melchardt, P. Obrtlíková, L. Smolej, T. Kozák, M. Steurer, J. Andel, S. Burgstaller, E. Mikušková, L. Gercheva, T. Nösslinger, T. Papajík, M. Ladická, M. Girschikofsky, M. Hrubiško, U. Jäger, D. Voskova, M. Pecherstorfer, E. Králiková, C. Burcoveanu, E. Spasov, A. Petzer, G. Mihaylov, J. Raynov, H. Oexle, A. Zabernigg, E. Flochová, S. Palášthy, O. Stehlíková, M. Doubek, P. Altenhofer, L. Weiss, T. Magnes, L. Pleyer, A. Klingler, J. Mayer, R. Greil,
- 520 9_
- $a No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL-8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab-containing induction treatment in first or second line that had achieved at least a PR. A randomization to rituximab maintenance treatment (375 mg/m2 q3 months for 2 years) vs observation was performed. In this cohort 22% of the patients (58/263) were classified as obese. The baseline response to induction treatment was inferior in obese patients with a lower CR rate (43.1% vs 60.5% in obese vs non-obese, P = 0.018) and with a lower rate of patients achieving MRD negativity after chemoimmunotherapy induction treatment (19.6% vs 35.8%, P = 0.02). The PFS outcome of obese patients was significantly worse in the observation group of the trial (24 vs 39 months median PFS, P = 0.03). However, in the rituximab maintenance group the outcome for obese vs non-obese was not different (P = 0.4). In summary, obesity was overall associated with a worse outcome of chemoimmunotherapy induction. However, rituximab maintenance treatment seems to be able to overcome this negative effect.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x farmakoterapie $x mortalita $7 D015451
- 650 _2
- $a udržovací chemoterapie $7 D060046
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a obezita $x komplikace $x mortalita $7 D009765
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a rituximab $x aplikace a dávkování $x terapeutické užití $7 D000069283
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Melchardt, Thomas $u Third Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria. Salzburg Cancer Research Institute (SCRI), Salzburg, Austria. Cancer Cluster Salzburg (CCS), Salzburg, Austria.
- 700 1_
- $a Obrtlíková, Petra $u First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Smolej, Lukáš $u Fourth Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic.
- 700 1_
- $a Kozák, Tomáš $u Department of Internal Medicine - Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Steurer, Michael $u Department of Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria.
- 700 1_
- $a Andel, Johannes $u Internal Medicine II, Hospital of Steyr, Steyr, Austria.
- 700 1_
- $a Burgstaller, Sonja $u Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Wels, Austria.
- 700 1_
- $a Mikušková, Eva $u Department of Hemato-oncology 2, National Cancer Institute Bratislava, Bratislava, Slovakia.
- 700 1_
- $a Gercheva, Liana $u Clinic of Hematology, University Hospital St Marina Varna, Varna, Bulgaria.
- 700 1_
- $a Nösslinger, Thomas $u Third Medical Department for Hematology and Oncology, Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna, Austria.
- 700 1_
- $a Papajík, Tomáš $u Department of Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Ladická, Miriam $u Department of Clinical Oncology 1, National Cancer Institute Bratislava, Bratislava, Slovakia.
- 700 1_
- $a Girschikofsky, Michael $u Interne Abteilung, Ordensklinikum Linz GmbH, Elisabethinen, Linz, Austria.
- 700 1_
- $a Hrubiško, Mikuláš $u Clinic of Hematology and Transfusiology, Slovak Medical University, University Hospital Bratislava, Bratislava, Slovakia.
- 700 1_
- $a Jäger, Ulrich $u Department of Medicine I, Division of Hematology and Hemostaeology, Medical University Vienna, Vienna, Austria.
- 700 1_
- $a Voskova, Daniela $u Department of Internal Medicine 3, Kepler Universitätsklinikum GmbH, Med Campus III., Linz, Austria.
- 700 1_
- $a Pecherstorfer, Martin $u Department of Internal Medicine 2, University Hospital Krems, Karl Landsteiner Private University of Health Sciences, Krems, Austria.
- 700 1_
- $a Králiková, Eva $u Department of Hematology, FNsP F D Roosevelta Banská Bystrica, Banska Bystrica, Slovakia.
- 700 1_
- $a Burcoveanu, Christina $u Clinic of Haematology, Regional Institute of Oncology Iasi, Iasi, Romania.
- 700 1_
- $a Spasov, Emil $u Clinic of Hematology, UMHAT St George and Medical University Plovdiv, Plovdiv, Bulgaria.
- 700 1_
- $a Petzer, Andreas $u Innere Medizin I, Ordensklinikum Linz GmbH, Linz, Austria.
- 700 1_
- $a Mihaylov, Georgi $u Hematological Clinic NSHATHD Sofia, Queen Joanna University Hospital, Sofia, Bulgaria.
- 700 1_
- $a Raynov, Julian $u Clinic of Medical Hematology, Military Medical Academy Sofia, Sofia, Bulgaria.
- 700 1_
- $a Oexle, Horst $u Innere Medizin, Landeskrankenhaus Hall, Hall in Tirol, Austria.
- 700 1_
- $a Zabernigg, August $u Innere Medizin II, Bezirkskrankenhaus Kufstein, Kufstein, Austria.
- 700 1_
- $a Flochová, Emília $u Department of Hematology and Transfusion, University Hospital Martin, Martin, Slovakia.
- 700 1_
- $a Palášthy, Stanislav $u Department of Clinical Hematology, FNsP, J A Reimana Prešov, Prešov, Slovakia.
- 700 1_
- $a Stehlíková, Olga $u Faculty of Medicine and CEITEC, University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Doubek, Michael $u Faculty of Medicine and CEITEC, University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Altenhofer, Petra $u Third Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria. Salzburg Cancer Research Institute (SCRI), Salzburg, Austria. Cancer Cluster Salzburg (CCS), Salzburg, Austria.
- 700 1_
- $a Weiss, Lukas $u Third Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria. Salzburg Cancer Research Institute (SCRI), Salzburg, Austria. Cancer Cluster Salzburg (CCS), Salzburg, Austria.
- 700 1_
- $a Magnes, Teresa $u Third Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria. Salzburg Cancer Research Institute (SCRI), Salzburg, Austria. Cancer Cluster Salzburg (CCS), Salzburg, Austria.
- 700 1_
- $a Pleyer, Lisa $u Third Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria. Salzburg Cancer Research Institute (SCRI), Salzburg, Austria. Cancer Cluster Salzburg (CCS), Salzburg, Austria.
- 700 1_
- $a Klingler, Anton $u Assign Data Management and Biostatistics GmbH, Innsbruck, Austria.
- 700 1_
- $a Mayer, Jiří $u Faculty of Medicine and CEITEC, University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Greil, Richard $u Third Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria. Salzburg Cancer Research Institute (SCRI), Salzburg, Austria. Cancer Cluster Salzburg (CCS), Salzburg, Austria.
- 773 0_
- $w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 8, č. 4 (2019), s. 1401-1405
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30888118 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214124820 $b ABA008
- 999 __
- $a ok $b bmc $g 1595113 $s 1113470
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 8 $c 4 $d 1401-1405 $e 20190319 $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
- LZP __
- $a Pubmed-20201125
